Cinq laboratoires initialement sélectionnés pour travailler ensemble dans le cadre d’un réseau centralisé afin d’évaluer et de comparer de manière fiable les réponses immunologiques générées par les candidats aux vaccins COVID-19
Fiabilité des vaccins
Un article de la Coalition pour les innovations en matière de préparation aux épidémies (CEPI) m’a paru intéressant sur la problématique de la future vaccination liée au Covid-19.
The Coalition for Epidemic Preparedness Innovations (CEPI) has today announced partnerships with five clinical sample testing laboratories to create a centralised global network to reliably assess and compare the immunological responses generated by COVID-19 vaccine candidates. Located across multiple regions globally, the laboratories initially selected for this vaccine-assessment network are: Nexelis (Canada) and Public Health England (PHE, UK), VisMederi Srl (Italy), Viroclinics-DDL (The Netherlands), icddr,b (formerly International Centre for Diarrhoeal Disease Research, Bangladesh), and Translational Health Sciences and Technological Institute (THSTI, India). The network will use the same testing reagents—originating in the labs of Nexelis and PHE—and follow common protocols to measure the immunogenicity of multiple COVID-19 vaccine candidates (both CEPI-funded and non-CEPI funded developers). This approach will ensure uniformity in assessment and informed identification of the most promising vaccine candidates. CEPI is actively negotiating with additional laboratories to participate in this network…
Archives
Coalition pour les innovations en matière de préparation aux épidémies (CEPI)